Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY P TILLINGHAST

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1447393301
CMS profile
65100
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,914.51

153 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $4,641.69 14
Food and Beverage $3,266.59 138
Education $6.23 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY P TILLINGHAST

NPI 1447393301 · CMS profile ID 65100

Allopathic & Osteopathic Physicians / Allergy & Immunology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

153 matching records · $7,914.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 153 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–153 of 153.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1401/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997003351 CMS
GlaxoSmithKline, LLC. $19.4501/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002579849 CMS
Mylan Specialty L.P. $13.9001/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039060071 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,311.18 71
PY2020 $2,108.22 27
PY2021 $5,759.36 69
PY2022 $2,713.64 114
PY2023 $7,914.51 153
PY2024 $255,569.43 89
PY2025 $1,424.70 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,407,897.52 161
PY2024 Principal investigator $2,577,229.58 370
PY2023 Principal investigator $1,820,825.73 287
PY2022 Principal investigator $1,679,702.14 114
PY2021 Recipient $2,640.00 2
PY2021 Principal investigator $610,606.06 108
PY2020 Principal investigator $870,068.70 73
PY2019 Recipient $87.86 1
PY2019 Principal investigator $1,763,849.37 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

161 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $3,990.00 12/19/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664287
Principal investigator 1 Verona Pharma, Inc. $16,083.99 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891971
Principal investigator 1 Verona Pharma, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891991
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,126.68 12/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045922
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,524.30 12/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045924
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,126.67 12/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045926
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,893.50 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190308822
Principal investigator 1 GlaxoSmithKline, LLC. $4,004.10 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109555
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $133.92 11/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045928
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $229.68 11/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045936
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $90.93 11/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046206
Principal investigator 1 Novartis Pharmaceuticals Corporation $45.16 11/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190308820
Principal investigator 1 Verona Pharma, Inc. $2,988.76 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891969
Principal investigator 1 GlaxoSmithKline, LLC. $3,664.77 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108140
Principal investigator 1 Verona Pharma, Inc. $23,765.36 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891967
Principal investigator 1 Verona Pharma, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891987
Principal investigator 1 Verona Pharma, Inc. $850.00 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891989
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $71.96 10/10/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045818
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.78 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308824
Principal investigator 1 GlaxoSmithKline, LLC. $11,016.00 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163428
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $38,384.24 10/01/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046220
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $71.96 09/26/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045816
Principal investigator 1 Verona Pharma, Inc. $2,988.76 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891851
Principal investigator 1 Incyte Corporation $250.00 09/10/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601468
Principal investigator 1 GlaxoSmithKline, LLC. $6,572.70 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163424
Principal investigator 1 Novartis Pharmaceuticals Corporation $40.50 08/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311031
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $107.94 08/15/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045814
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $993.16 08/15/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046222
Principal investigator 1 GlaxoSmithKline, LLC. $761.00 08/14/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109514
Principal investigator 1 GlaxoSmithKline, LLC. $16,978.50 08/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109527
Principal investigator 1 GlaxoSmithKline, LLC. $1,587.78 08/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109541
Principal investigator 1 AstraZeneca Pharmaceuticals LP $72,071.00 08/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185547025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $56,231.55 08/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046218
Principal investigator 1 Verona Pharma, Inc. $10,000.00 07/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891879
Principal investigator 1 Verona Pharma, Inc. $2,000.00 07/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891881
Principal investigator 1 GlaxoSmithKline, LLC. $3,031.19 07/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108126
Principal investigator 1 Genentech, Inc. $188.00 07/18/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664283
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,215.00 07/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine No dispute reported 06/30/2026 1185547035
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $71.96 07/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045812
Principal investigator 1 CIPLA USA INC. $109.47 07/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER, LLC
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932247
Principal investigator 1 Incyte Corporation $100.00 07/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601464
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 07/01/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045810
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 06/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045808
Principal investigator 1 GlaxoSmithKline, LLC. $12,353.10 06/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184207825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184208879
Principal investigator 1 GlaxoSmithKline, LLC. $990.00 06/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109535
Principal investigator 1 Genentech, Inc. $63.00 05/23/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664261
Principal investigator 1 Genentech, Inc. $567.00 05/23/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664269
Principal investigator 1 Genentech, Inc. $891.00 05/23/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664278
Principal investigator 1 Genentech, Inc. $752.00 05/21/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664258
Principal investigator 1 Genentech, Inc. $750.00 05/21/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664273
Principal investigator 1 GlaxoSmithKline, LLC. $17,005.50 05/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163420
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,595.77 05/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046400
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,847.00 05/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046392
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,410.44 05/14/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046394
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184193555
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601460
Principal investigator 1 AstraZeneca Pharmaceuticals LP $160,166.10 05/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185547033
Principal investigator 1 GlaxoSmithKline, LLC. $5,492.70 04/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108134
Principal investigator 1 AstraZeneca Pharmaceuticals LP $125,331.52 04/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185547003
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,747.06 04/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547021
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,561.35 04/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185547023
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $143.92 04/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046046
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,629.76 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547013
Principal investigator 1 GlaxoSmithKline, LLC. $9,378.90 04/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109549
Principal investigator 1 CIPLA USA INC. $875.00 04/01/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER, LLC
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932243
Principal investigator 1 CIPLA USA INC. $3,600.00 04/01/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER, LLC
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $215.88 03/12/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046044
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,880.60 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185547007
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,280.00 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185547029
Principal investigator 1 AstraZeneca Pharmaceuticals LP $48,223.00 03/05/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185547005
Principal investigator 1 AstraZeneca Pharmaceuticals LP $84,977.96 03/05/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185547017
Principal investigator 1 Genentech, Inc. $3,564.00 02/28/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664254
Principal investigator 1 GlaxoSmithKline, LLC. $21,976.20 02/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109560
Principal investigator 1 Incyte Corporation $1,443.60 02/19/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601444
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,690.77 02/13/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER LLC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190309838
Principal investigator 1 GlaxoSmithKline, LLC. $13,038.30 02/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192109520
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,747.26 01/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547037
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,590.16 01/15/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547027
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,261.37 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547011
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,108.43 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185547039
Principal investigator 1 AstraZeneca Pharmaceuticals LP $123,312.00 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185547041
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,968.82 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547009
Principal investigator 1 CIPLA USA INC. $17,058.99 01/07/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER, LLC
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932241
Principal investigator 1 AstraZeneca Pharmaceuticals LP $48,124.28 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547031
Principal investigator 1 GlaxoSmithKline, LLC. $32.31 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163415
Principal investigator 1 Incyte Corporation $2,150.00 01/03/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601448
Principal investigator 1 Incyte Corporation $3,500.00 01/03/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601452
Principal investigator 1 AstraZeneca Pharmaceuticals LP $120,830.80 01/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185547015
Principal investigator 1 Incyte Corporation $74.34 01/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601436
Principal investigator 1 Incyte Corporation $27.84 01/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601440
Principal investigator 1 Incyte Corporation $251.42 01/02/2025 Non-covered Recipient Entity
THE CLINICAL RESEARCH CENTER CRC, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240601456
Principal investigator 1 Novartis Pharmaceuticals Corporation $295.80 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190311027
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,678.04 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER LLC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190311029